UNITED STATES

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549 

FORM 8-K 

CURRENT REPORT 

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 

Date of Report (Date of earliest event reported): February 2, 2018 

THE CLOROX COMPANY

(Exact name of registrant as specified in its charter)

  [DATA_TABLE_REMOVED] 

1221 Broadway, Oakland, California 94612-1888

(Address of principal executive offices) (Zip code) 

(510) 271-7000

(Registrant's telephone number, including area code) 

Not applicable 

(Former name or former address, if changed since last report) 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: 

[ ] Written communications pursuant to Rule 425 Under the Securities Act (17 CFR 230.425) 

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2). 

Emerging growth company ¨ 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 Item 2.02 Results of Operations and Financial Condition 

 On February 2, 2018, The Clorox Company issued a press release announcing its financial results for its second quarter ended December 31, 2017. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. 

 Item 7.01 Regulation FD Disclosure 

 Attached hereto as Exhibit 99.2 and incorporated herein by reference is supplemental financial information. 

 Item 9.01 Financial Statements and Exhibits 

 (d) Exhibits 

 See the Exhibit Index below. 

 EXHIBIT INDEX [DATA_TABLE_REMOVED] 

SIGNATURES 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 

THE CLOROX COMPANY 

 Date: February 2, 2018 By:   /s/ Laura Stein 

    Executive Vice President – 

    General Counsel and Corporate Affairs